Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with peginterferon ALFA-2A

Journal of Infectious Diseases

Volumn 205, Issue 9, 2012, Pages 1443-1447

  Hubbard, Jonathan J ^a   Greenwell Wild, Teresa ^b   Barrett, Lisa ^a   Yang, Jun ^c   Lempicki, Richard A ^c   Wahl, Sharon M ^b   Asmuth, David M ^d   Murphy, Robert L ^e   Pollard, Richard B ^d   Kottilil, Shyam ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c SAIC FREDERICK INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A;

ARTICLE; CLINICAL ARTICLE; CYTOKINE RESPONSE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; INTERFERON INDUCIBLE GENE; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS LOAD;

ANTIVIRAL AGENTS; GENE EXPRESSION REGULATION; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RNA, VIRAL; VIRAL LOAD;

EID: 84861543028     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis211     Document Type: Article

References (15)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147:258-67.
2. Herbeuval JP, Shearer GM. HIV-1 immunopathogenesis: how good interferon turns bad. Clin Immunol 2007; 123:121-8.
3. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-7.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
5. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14:778-809, table of contents.
6. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436:967-72.
7. Yamamoto JK, Barre-Sinoussi F, Bolton V, Pedersen NC, Gardner MB. Human alpha-and beta-interferon but not gamma-suppress the in vitro replication of LAV, HTLV-III, and ARV-2. J Interferon Res 1986; 6:143-52.
8. Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med 2006; 203:41-6.
9. Kottilil S, Yan MY, Reitano KN, et al. Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. Hepatology 2009; 50:34-45.
10. Asmuth DM, Murphy RL, Rosenkranz SL, et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis 2010; 201:1686-96.
11. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290:1972-4.
12. Shirazi Y, Pitha PM. Alpha interferon inhibits early stages of the human immunodeficiency virus type 1 replication cycle. J Virol 1992; 66:1321-8.
13. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 1998; 95:15623-8.
14. Taylor MW, Tsukahara T, Brodsky L, et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 2007; 81:3391-401.
15. Taylor MW, Grosse WM, Schaley JE, et al. Global effect of PEG-IFNalpha and ribavirin on gene expression in PBMC in vitro. J Interferon Cytokine Res 2004; 24:107-18.